Platinum-sensitive ovarian cancer

What changed: Platinum-sensitive ovarian cancer

Cancer page →

Every dated change on the records linked to Platinum-sensitive ovarian cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Trial result7Milestone8This record1

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-17This recordPlatinum-sensitive ovarian cancer
Facts on this page last checked
When this page itself was last checked or edited.

2023 · 2

2022 · 2

2020 · 2

2019 · 3

2018 · 2

2014 · 1

2014MilestoneOlaparib
Olaparib approved as the first PARP inhibitor, for BRCA-mutant relapsed disease
A milestone in how this cancer is treated.

2011 · 1

2011Trial resultGOG-0218 & ICON7 (bevacizumab)
GOG-0218 & ICON7 (bevacizumab) reported
GOG-0218 PFS 14.

2005 · 1

2005MilestonePARP inhibitors
Synthetic lethality of PARP inhibition in BRCA-deficient cells
A milestone in how this cancer is treated.

1989 · 1

1989MilestoneCarboplatin
Carboplatin approved; platinum-free interval emerges as the guide to re-treatment
A milestone in how this cancer is treated.